

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/001393

International filing date: 13 January 2005 (13.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/536,766
Filing date: 15 January 2004 (15.01.2004)

Date of receipt at the International Bureau: 02 May 2005 (02.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1313986

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 26, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/536,766

FILING DATE: *January 15, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/01393*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

	Large/Small Entity		Fee Code
10. Filing Fee	\$160/\$80	+80	114/214
11. If "non-English" box 2 is X'd, add Rule 17(k) processing fee	\$130	+0	139
12. If "assignment" box 5 is X'd, add recording fee.	\$40	+0	581
13.	TOTAL FEE =		\$80

Our Deposit Account No. 16-1805
Our Order No.

81476

307250

C#


M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-17 (missing or insufficient fee only) now or hereafter relative to this application or credit any overpayment, to our Account/Order Nos. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached.

725 South Figueroa StreetSuite 2800
Los Angeles, CA 90017-5406
Tel: (213) 488-7100

Atty/Sec: SDL/SBK

Pillsbury Winthrop LLP
Intellectual Property Group
By Atty: Seth D. Levy

Sig: 

Reg. No. 44,869

Fax: (213) 629-1033
Tel: (213) 488-7100

NOTE: File in duplicate with 2 post card receipts (PAT-103) & attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

JULIAN P. WHITELEGGE

Group Art Unit: Unknown

Appln. No.: Unassigned

Examiner: Unassigned

Filed: January 15, 2004

Atty Dkt: 81476-307250
C# M#

Title: ***SYSTEM AND METHOD FOR EXPRESSION
PROTEOMICS BASED ON ISOTOPE RATIO
MODIFICATION***

CERTIFICATE OF MAILING VIA U.S. EXPRESS MAIL

Express Mail Label No. EV235025255US

Date of Deposit: January 15, 2004

Mail-Stop PROVISIONAL APPLICATION

Commissioner for Patents

P. O. BOX 1450

Alexandria, Virginia 22313-1450


Dear Sir:

I hereby certify that the following documents:

- X Request for Filing Provisional Application
- X Provisional patent application (4 pages of specification, 1 drawing sheet)
- X Check in the amount of \$80 to cover the filing fee
- X Return postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service with sufficient postage under 37 CFR 1.10 on the date indicated above and are addressed to: Mail-Stop PROVISIONAL APPLICATION, Commissioner for Patents, P. O. BOX 1450, Alexandria, Virginia 22313-1450.

Dated: January 15, 2004



Sherry B. Kolber

APPLICATION FOR A PROVISIONAL
UNITED STATES PATENT
IN THE NAME OF

Julian P. Whitelegge

for

**SYSTEM AND METHOD FOR EXPRESSION PROTEOMICS BASED ON ISOTOPE
RATIO MODIFICATION**

Assigned to:

CEDARS-SINAI MEDICAL CENTER

Prepared by:

PILLSBURY WINTHROP LLP
725 South Figueroa Street, Suite 2800
Los Angeles, California 90017-5406
Telephone: (213) 488-7100
Facsimile: (213) 629-1033

Attorney Docket No.
81476-307250

Express Mail Mailing Label No.:
EV 235025055 US

SYSTEM AND METHOD FOR EXPRESSION PROTEOMICS BASED ON ISOTOPE RATIO MODIFICATION

5 FIELD OF THE INVENTION

The invention relates to expression proteomics, and, particularly, to a system and method for analyzing expression proteomics based on a modification or modifications to isotope ratio.

BACKGROUND OF THE INVENTION

10 There are a number of stable isotope strategies currently used to study biological systems. Each of these strategies is predicated on the use of a complete or near-complete isotope swap in the molecules, sample, or entire organism being analyzed. This process is sometimes referred to as "conversion" with reference to the molecules, sample, or entire organism.

In general, a non-natural isotope is "swapped" for the naturally occurring variety. For
15 instance, ^{15}N may be swapped for ^{14}N , ^{13}C for ^{12}C , or ^{18}O for ^{16}O . A complete (or near-complete) isotope swap may be achieved by any number of strategies well known to those of skill in the art. By way of example, these strategies may include isotope-coded affinity tag ("ICAT") technology, stable isotope labeling with amino acids in cell culture ("SILAC"), enzymatic molecular introduction (*i.e.*, exchange) of ^{18}O , and growth of a biological sample, a
20 cell culture, or an entire organism in stable isotopes. By inducing an isotope swap of this nature, it becomes possible to examine a range of biological processes at the molecular level.

While this technology has important implications and uses in the study of molecular biology, it is significantly limited in its applications. It is generally not applicable, for example, to the study of living humans and other animals. Inducing a complete swap of isotopes in living
25 humans and other animals -- even if it could be achieved, which is by no means a simple assumption -- is likely to present significant health concerns, and to be both tremendously expensive and time-consuming. Thus, in order to implement isotope swapping techniques in the study of such systems, a different methodology is believed to be required. Such a methodology may have a dramatic impact on the study of biology and biological systems, and particularly
30 human and animal biology, as well as other systems that may not be appropriate for study in connection with the conventional methods described above.

DESCRIPTION OF THE INVENTION

The present invention is based on a novel approach to the study of molecular biology, by inducing subtle modifications in the isotopes of target molecules. “Subtle,” as used herein with reference to the modification of isotopes included in target molecules, is defined as a “swapping”
5 of, on average, substantially less than all of the isotopes in a target molecule. These subtle modifications may be induced with reference to any suitable target isotope or isotopes, which may include, but are in no way limited to, ^{13}C for ^{12}C , ^{18}O for ^{16}O , and ^{15}N for ^{14}N . Additional isotopes suitable for subtle modification in accordance with alternate embodiments of the present invention will be readily appreciated by those of skill in the art; for instance, deuterium may be
10 swapped for hydrogen.

Subtle alteration of the ratio of ^{13}C to ^{12}C may be particularly advantageous in connection with the methods of the present invention, insofar as these methods are implemented in connection with proteomics. Carbon is the most abundant constituent of proteins, and, thus, a small change in the ratio of ^{13}C to ^{12}C has the most dramatic effect upon isotopic distribution;
15 changing this ratio from 100:1 to 100:2 (or 200:1), for instance, may have quite a dramatic effect. In the context of proteomics, this subtle alteration of isotopic ratio can be measured from the isotopic distribution of peptide ions; thereby providing a means of stable isotope tagging that does not require full conversion to a non-natural isotope. For example, Fig. 1 illustrates a MALDI readout from *Synechocystis* cultures in which subtle modifications of target molecules
20 were induced (normal IR, +1.5%, +3.0% and +6% ^{13}C , respectively; from top to bottom of Figure), in accordance with an embodiment of the present invention.

The methods of the present invention are by no means limited to the study of proteomics, however. In fact, the invention may find application in a host of biological systems, as well as non-biological systems (*i.e.*, in the study of any system in which isotopes may be
25 subtly modified and thereafter analyzed by the methods described herein).

Methods for inducing the subtle modifications incorporated in various aspects of the present invention will similarly be recognized and may be readily implemented by those of skill in the art without undue experimentation. In addition to the use of variants of the technology described above (*i.e.*, ICAT, SILAC, enzymatic exchange, and growth in stable isotopes), other
30 means for inducing the subtle modification of isotopes can be readily ascertained. For example, a living animal may be fed a diet that includes the non-natural isotope or isotopes sought to be

introduced into their internal physiology; diet influences actual isotope ratios in animals, including humans. Such a diet may include, for example, food (*e.g.*, animal chow) supplemented with the non-natural isotope, or, in another embodiment of the invention, the diet may include deuterated or deuterium-enriched water. Alternatively, the isotope may be introduced by
5 pharmacological means (*e.g.*, a diet supplement), or by other conventional forms of administration (*e.g.*, injection of saline consisting of the non-natural isotope).

Once the target molecule (or molecules) has been subtly modified, it may be studied by a number of different technologies. For example, isotope ratio mass spectrometry (“IRMS”) may be employed, whereby levels of different isotopes (*e.g.*, ^{13}C and ^{12}C) may be measured after
10 conversion to carbon dioxide (*e.g.*, by combustion). Alternatively, the isotope ratio may be measured by calculation from the peptide mass spectra obtained by various forms of mass spectrometry (*e.g.*, MS-MS). Specific protein molecules can be identified by MS-MS in connection with an appropriate database search, or isotopic distribution can be estimated using averagine (*i.e.*, a model amino acid with elemental components occurring at frequencies deduced
15 from the PIR database). In particular embodiments of the invention, high resolution mass spectrometry, such as Fourier transform mass spectrometry (“FTMS”), may be particularly advantageous and accurate. Moreover, in instances where peptide sequences (and, thus, elemental compositions) are known, the measurements attainable on high-resolution instrumentation, such as mass spectrometers employing FTMS, may be highly accurate.

The present invention has a range of applications. In one embodiment, the invention may be used in connection with isotope coding by subtle alteration of isotope ratio in proteins. This may be particularly useful in connection with proteomics. For instance, one may study the relative expression of various proteins in a biological system. Two (or more) samples can be distinguished by their isotope ratios; thereby allowing mixing and relative expression
20 measurement by comparison of peak height/areas (*i.e.*, in a MALDI readout). The isotope ratio of a peptide in a mixture is determined by relative contribution from non-labeled as compared with labeled material.


In another embodiment, the present invention may be used to study protein turnover (*e.g.*, one may monitor metabolic or transcriptional activity by seeking out newly altered or transcribed
30 proteins, respectively). Protein turnover may be measured using pulse-phase protocols. For instance, if a human begins to eat food with an altered isotope ratio, then this will first be

observed in rapidly turning over proteins. Slow turning over proteins will be last to manifest the change in isotope ratio.


Among the benefits of employing the methods of the present invention in connection with, for example, proteomics, is the significant cost savings and the ability to study systems that
5 were heretofore impossible to study by way of isotope swapping.

While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. Such alternate methodologies and procedures may be readily implemented without
10 undue experimentation. The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive.


Voyager Spec #1[BP = 1468.5, 133]



<<rrhWHITELEGGE010904_0015>> Voyager Spec #1[BP = 1469.5, 729]



<<rrhWHITELEGGE010904_0028>> Voyager Spec #1[BP = 2925.2, 131]



<<rrhWHITELEGGE010904_0037>> Voyager Spec #1[BP = 1470.5, 121]

